Synergistic Cytotoxic Effect of Sulindac and Pyrrolidine Dithiocarbamate Against Ovarian Cancer Cells

Overview

Journal Oncol Rep

Specialty Oncology

Date 2012 Jan 24

PMID 22266802

Citations 1

Authors

Anna Jakubowska-Mucka

Jacek Sienko

Lukasz Zapala

Rafal Wolny

Witold Lasek

Affiliations

Soon will be listed here.

Abstract

Sulindac, a non-steroidal anti-inflammatory drug, suppresses carcinogenesis and inhibits growth of tumor cells. Pyrrolidine dithiocarbamate (PDTC), a potent NF-κB inhibitor, has been also identified as a potential anti-neoplastic agent. We hypothesized that combination of sulindac and PDTC could result in augmentation of cytotoxicity against ovarian cancer cells. The effect of sulindac and PDTC was examined on several ovarian cancer lines. Tumor cell viability was assessed using the MTT assay. Annexin-V/PI staining was used to detect apoptosis, cell cycle distribution was analyzed in FACS, and expression of cellular proteins was detected by western blotting. Incubation of OVA-14, OVP-10 and CAOV-1 ovarian cancer cells with sulindac and PDTC resulted in significantly greater inhibition of cell viability compared to either compound alone. In a model of OVA-14 cells it was evident that this effect was not related to the expression of COX enzymes since both active (sulindac sulfide) and inactive (sulindac) in vitro compounds affected the growth of tumor cells to a similar extent and synergized in cytotoxicity with PDTC. Combination of sulindac and PDTC lead to G0 arrest and massive apoptosis in co-treated cultures. Western blotting analysis argued for induction of the mitochondrial apoptotic pathway. These data demonstrate the synergistic cytotoxic effect of sulindac and PDTC on ovarian cancer cells through apoptosis and cell cycle arrest and prompt to test the efficacy of this combination in animal models.

Citing Articles

BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells.

Chen L, Ruan Y, Wang X, Min L, Shen Z, Sun Y J Gastroenterol. 2013; 49(5):864-74.

PMID: 23846545 DOI: 10.1007/s00535-013-0848-4.

References

Liu G, Wang S, Wang B, Kong B . Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer. 2006; 16(5):1777-82. DOI: 10.1111/j.1525-1438.2006.00652.x. View

Karl T, Seibert N, Stohr M, Osswald H, Rosl F, Finzer P . Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2006; 245(1-2):103-11. DOI: 10.1016/j.canlet.2005.12.034. View

Cuzick J, Otto F, Baron J, Brown P, Burn J, Greenwald P . Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10(5):501-7. DOI: 10.1016/S1470-2045(09)70035-X. View

Yamamoto Y, Yin M, Lin K, Gaynor R . Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999; 274(38):27307-14. DOI: 10.1074/jbc.274.38.27307. View

Andrews P, Zhao X, Allen J, Li F, Chang M . A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2007; 61(2):203-14. DOI: 10.1007/s00280-007-0462-3. View

Morais C, Gobe G, Johnson D, Healy H . Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis. 2009; 15(4):412-25. DOI: 10.1007/s10495-009-0414-y. View

Chen D, Peng F, Cui Q, Daniel K, Orlu S, Liu J . Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci. 2005; 10:2932-9. DOI: 10.2741/1749. View

Nai Y, Jiang Z, Wang Z, Li N, Li J . Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice. JPEN J Parenter Enteral Nutr. 2007; 31(1):18-25. DOI: 10.1177/014860710703100118. View

Yip-Schneider M, Wu H, Ralstin M, Yiannoutsos C, Crooks P, Neelakantan S . Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007; 6(6):1736-44. DOI: 10.1158/1535-7163.MCT-06-0794. View

10.

Gu J, Young E, Busby B, Covington J, Johnson J . Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice. Cancer Biol Ther. 2009; 8(6):514-21. DOI: 10.4161/cbt.8.6.7689. View

11.

Munkarah A, Ali-Fehmi R . COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol. 2005; 17(1):49-53. DOI: 10.1097/00001703-200502000-00009. View

12.

Verheul H, Panigrahy D, Yuan J, DAmato R . Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer. 1999; 79(1):114-8. PMC: 2362163. DOI: 10.1038/sj.bjc.6690020. View

13.

Govindan R, Wang X, Baggstrom M, Burdette-Radoux S, Hodgson L, Vokes E . A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. J Thorac Oncol. 2009; 4(2):220-6. DOI: 10.1097/JTO.0b013e3181951eb0. View

14.

Gupta R, Tejada L, Tong B, Das S, Morrow J, Dey S . Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003; 63(5):906-11. View

15.

Morais C, Gobe G, Johnson D, Healy H . Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis. 2009; 12(4):365-79. DOI: 10.1007/s10456-009-9158-0. View

16.

Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T . Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol. 2010; 116(2):157-62. DOI: 10.1016/j.ygyno.2009.10.076. View

17.

Kim J, Baek S, Sali T, Eling T . The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther. 2005; 4(3):487-93. DOI: 10.1158/1535-7163.MCT-04-0201. View

18.

Ledermann J, Raja F . Targeted trials in ovarian cancer. Gynecol Oncol. 2010; 119(1):151-6. DOI: 10.1016/j.ygyno.2010.05.008. View

19.

Seo A, Hong S, Shin J, Park I, Hong N, Kim D . Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis. 2009; 14(7):913-22. DOI: 10.1007/s10495-009-0367-1. View

20.

Nakanishi C, Toi M . Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005; 5(4):297-309. DOI: 10.1038/nrc1588. View